NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/25/2025
Back to search
Official data from USPTO
OXFORD BIOMEDICA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
OXFORD BIOMEDICA
ST13
US500000087488957Class
1, 5, 42, 44
Filing
87488957
Registration
5451207
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
03/19/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
06/14/2017
Registration date
04/24/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/25/2025
Last transaction
03/19/2025
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
11
Owner location
Oxford, GB
Examiner
VAGHANI, MAYUR
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Oxford BioMedica (UK) Limited
Representatives
Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicalsprecursors for in vitro genetic engineering use; polypeptides for in vitro research usemonoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; laboratory chemicalsan antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research useviruses for laboratory and scientific research usecell cultures for laboratory and scientific research useplasmids and cultures of micro-organisms for laboratory and scientific research usenucleic acid sequences for laboratory and scientific research usecloning vehicles in the nature of plasmidsmicrobes and chemical reagents for DNA cloning for laboratory and scientific research usechemicals for laboratoryscientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research usein vitro and in vivo use
Class 5
Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infectionscancerHIV and AIDSneurodegenerative diseasesdiseases of the eyeleukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic productsgene delivery pharmaceuticals; small moleculesvaccinesbiologicsenzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viralretroviral and non-viral vectorsall for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparationsfor use in gene therapy and for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders
Class 42
Scientificpharmaceutical and medical research and development; genetic engineering servicesbiotechnology servicesresearch and development for new products in the field of biotechnologyadvisory services relating to gene therapy products and clinical trialsconducting clinical trials
Class 44
Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatmentrelief and/or prevention of cancerinfectious diseasesfungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders and contraceptives
Publications
History of USPTO decisions and trademark events.
25 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/25/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/24/2025
E815
TEAS SECTION 8 & 15 RECEIVED
10/17/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/24/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/08/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/08/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
04/24/2018
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
03/20/2018
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/20/2018
IUCN
NOTICE OF ALLOWANCE CANCELLED
03/06/2018
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
03/06/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/02/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2017
PUBO
PUBLISHED FOR OPPOSITION
11/07/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/18/2017
ALIE
ASSIGNED TO LIE
10/01/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/18/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
09/18/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/18/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
09/18/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/18/2017
DOCK
ASSIGNED TO EXAMINER
09/13/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/21/2017
NWAP
NEW APPLICATION ENTERED
06/17/2017
Continuous trademark protection
Get notified about every new filing that threatens OXFORD BIOMEDICA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.